AstraZeneca Pharma India Receives Tax Appeal Order Over Supplies under Patient Access Program
AstraZeneca Pharma India Ltd has received an order from the Deputy Commissioner of State Tax (Appeal) regarding a matter concerning supplies made by the company under its Patient Access Program for the financial year 2018-19. The order was issued on June 3, 2026.The appeal relates to adjustments initially made by the Assistant Commissioner of State Tax Investigation. These adjustments have been upheld by the Deputy Commissioner of State Tax (Appeal).
This legal development follows an earlier intimation that had been previously provided regarding the matter. The company is planning to contest the outcome in due course.
Key details pertaining to the dispute and its financial scope are as follows:
| Particulars | Details |
|---|---|
| Opposing Party | Deputy Commissioner of State Tax (Appeal) |
| Financial Year | 2018-19 |
| Subject Matter | Adjustments concerning supplies made under Patient Access Program |
| Quantum of Claims | Rs. 9.24 crores (approx.), excluding interest and penalty |
| Next Legal Step | The matter will be challenged before the GST Appellate Tribunal (GSTAT) by filing an appeal |
ASTRAZEN Stock Price Movement
AstraZeneca Pharma India Limited settled at ₹8514.5 today after shedding 0.20% in post-market trading. The stock traded within a range defined by the intraday low of ₹8401.5 and a high of ₹8595, with a total volume of 8,255 shares reported.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.